[go: up one dir, main page]

DE60039416D1 - Verwendung vom vaskulären endothelialen wachstumsfaktor 2 (vegf-2) - Google Patents

Verwendung vom vaskulären endothelialen wachstumsfaktor 2 (vegf-2)

Info

Publication number
DE60039416D1
DE60039416D1 DE60039416T DE60039416T DE60039416D1 DE 60039416 D1 DE60039416 D1 DE 60039416D1 DE 60039416 T DE60039416 T DE 60039416T DE 60039416 T DE60039416 T DE 60039416T DE 60039416 D1 DE60039416 D1 DE 60039416D1
Authority
DE
Germany
Prior art keywords
vegf
growth factor
vascular endothelial
endothelial growth
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60039416T
Other languages
English (en)
Inventor
Craig A Rosen
Ralph Alderson
Robert Melder
Viktor Roschke
Steven M Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Application granted granted Critical
Publication of DE60039416D1 publication Critical patent/DE60039416D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
DE60039416T 1999-02-08 2000-02-07 Verwendung vom vaskulären endothelialen wachstumsfaktor 2 (vegf-2) Expired - Lifetime DE60039416D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11917999P 1999-02-08 1999-02-08
US11992699P 1999-02-12 1999-02-12
US13779699P 1999-06-03 1999-06-03
US17150599P 1999-12-22 1999-12-22
PCT/US2000/003047 WO2000045835A1 (en) 1999-02-08 2000-02-07 Vascular endothelial growth factor-2

Publications (1)

Publication Number Publication Date
DE60039416D1 true DE60039416D1 (de) 2008-08-21

Family

ID=27494239

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60039416T Expired - Lifetime DE60039416D1 (de) 1999-02-08 2000-02-07 Verwendung vom vaskulären endothelialen wachstumsfaktor 2 (vegf-2)

Country Status (10)

Country Link
EP (2) EP1156820B1 (de)
JP (1) JP2002539082A (de)
KR (1) KR20010101981A (de)
CN (1) CN1433318A (de)
AT (1) ATE400289T1 (de)
AU (1) AU2757000A (de)
CA (1) CA2361615A1 (de)
DE (1) DE60039416D1 (de)
HK (1) HK1042052A1 (de)
WO (1) WO2000045835A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
JPH09510093A (ja) 1994-03-08 1997-10-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 血管内皮細胞増殖因子２
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
WO2000058511A1 (en) 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
WO2001062942A2 (en) 2000-02-25 2001-08-30 Ludwig Institute For Cancer Research MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS
KR100777195B1 (ko) 2000-04-03 2007-11-19 산텐 세이야꾸 가부시키가이샤 송달성 물질 및 이를 이용한 약물 송달 시스템
NZ518077A (en) 2000-08-04 2003-11-28 Human Genome Sciences Inc Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
EP1341914A2 (de) 2000-12-07 2003-09-10 Sangamo Biosciences Inc. Regulation der angiogenese durch zinkfinger-proteine
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CN1494552A (zh) 2001-01-19 2004-05-05 ·��ά��֢�о�Ժ Flt4(VEGFR-3)作为靶用于肿瘤成像和抗肿瘤治疗
EP1385864B1 (de) 2001-04-13 2010-06-09 Human Genome Sciences, Inc. Anti-VEGF-2 Antikörper
JP4838968B2 (ja) * 2001-09-28 2011-12-14 参天製薬株式会社 薬物−ポリエチレングリコール結合体を含有する眼組織内注入剤
WO2003028765A1 (en) * 2001-09-28 2003-04-10 Santen Pharmaceutical Co., Ltd. Injections for eye tissue containing drug bound to polyethylene glycol
JP4988606B2 (ja) 2005-02-28 2012-08-01 サンガモ バイオサイエンシズ インコーポレイテッド 抗血管新生方法及び組成物
JP2009523807A (ja) * 2006-01-18 2009-06-25 ザ ジェネラル ホスピタル コーポレイション リンパ機能を高める方法
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA2828811C (en) 2011-03-03 2021-09-21 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
CA2878640C (en) 2012-07-13 2023-10-24 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
ES2771478T3 (es) 2013-02-18 2020-07-06 Vegenics Pty Ltd Moléculas de unión a ligando y usos de las mismas
US11390666B2 (en) * 2017-06-07 2022-07-19 Philogen S.P.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
CN111291789B (zh) * 2020-01-19 2022-07-05 华东交通大学 基于多阶段多特征深度融合的乳腺癌图像识别方法及系统
CN116406303B (zh) * 2020-09-04 2025-07-29 孔二艳 将gfap氨基酸位点作为神经退行性疾病治疗靶标的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932540A (en) * 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
JPH09510093A (ja) * 1994-03-08 1997-10-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 血管内皮細胞増殖因子２
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product

Also Published As

Publication number Publication date
WO2000045835A1 (en) 2000-08-10
EP1985632A3 (de) 2008-11-12
CN1433318A (zh) 2003-07-30
KR20010101981A (ko) 2001-11-15
HK1042052A1 (zh) 2002-08-02
EP1156820B1 (de) 2008-07-09
JP2002539082A (ja) 2002-11-19
EP1985632A2 (de) 2008-10-29
EP1156820A4 (de) 2004-12-22
CA2361615A1 (en) 2000-08-10
EP1156820A1 (de) 2001-11-28
ATE400289T1 (de) 2008-07-15
AU2757000A (en) 2000-08-25

Similar Documents

Publication Publication Date Title
ATE400289T1 (de) Verwendung vom vaskulären endothelialen wachstumsfaktor 2 (vegf-2)
NO2019045I1 (no) Ranibizumab - Forlenget SPC
ATE330630T1 (de) Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose
FR07C0017I2 (fr) Anticorps anti-vegf
FI962350A0 (fi) BPM-12, BMP-13 sekä niiden jännettä indusoivat koostumukset
DE69839060D1 (de) Vegi, ein inhibitor der angiogenese und des tumorwachstums
ATE277034T1 (de) Liponsaürederivate und deren verwendung bei der behandlung von krankheiten
DE69920031D1 (de) Verwendung von vegf-c und vegf-d genen oder proteinen zur vorbeugung der restenose
ATE438361T1 (de) Stent beschichtet mit dna
ATE262537T1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
ATE253059T1 (de) Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2- one und ihre verwendung als lipase-hemmer
DE69934336D1 (de) Verwendung von halofuginone zur behandlung von urethralstriktur
NO20016326L (no) Anvendelse av proteinet UK 114 for å hindre avstötning av organtransplantatet
ATE209910T1 (de) Verwendung von 6,7-substituierter 2- aminotetraline zur behandlung von zytokin- vermittleten entzündungszuständen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition